Delfi Diagnostics stock

Delfi Diagnostics Stock

HealthTech

Looking to sell Delfi Diagnostics stock or options?

Contact us
Founded: 2019Funding to Date: $326M
Visit website

Delfi Diagnostics has developed a blood test system specifically designed for early cancer detection. The company's medical system utilizes machine learning to focus on the research and development of pioneering blood and genome testing to identify and intercept cancer at a curable stage. This technology allows healthcare professionals to discover previously unnoticed cancer-related cell-free DNA fragments and administer effective treatments for faster healing.

Investors Include:

Blue Owl Capital, Foresite Capital, Initiate Ventures, Point Field Partners, Merck Global Health Innovation Fund, Eli Lilly and Company, Johns Hopkins Technology Ventures, Osage University Partners, Cowen Healthcare Investments, Point72 Ventures, PTX Capital, Open Field Capital, Northpond Ventures, Illumina Ventures, Samsara BioCapital, AV8 Ventures, DFJ Growth, Brown Advisory, Menlo Ventures, OrbiMed, T. Rowe Price Group, Rock Springs Capital, Windham Capital Partners.